R Squared Ltd Takes Position in Alnylam Pharmaceuticals, Inc. $ALNY

R Squared Ltd acquired a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the third quarter, Holdings Channel reports. The fund acquired 1,660 shares of the biopharmaceutical company’s stock, valued at approximately $757,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Brighton Jones LLC acquired a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $243,000. Geneos Wealth Management Inc. raised its holdings in Alnylam Pharmaceuticals by 372.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock valued at $60,000 after buying an additional 175 shares during the period. AlphaQuest LLC acquired a new position in Alnylam Pharmaceuticals in the second quarter valued at about $43,000. Nisa Investment Advisors LLC boosted its stake in Alnylam Pharmaceuticals by 1.1% during the second quarter. Nisa Investment Advisors LLC now owns 8,242 shares of the biopharmaceutical company’s stock worth $2,688,000 after buying an additional 87 shares during the period. Finally, Envestnet Asset Management Inc. increased its position in shares of Alnylam Pharmaceuticals by 33.0% during the second quarter. Envestnet Asset Management Inc. now owns 95,796 shares of the biopharmaceutical company’s stock valued at $31,238,000 after acquiring an additional 23,749 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analyst Upgrades and Downgrades

ALNY has been the topic of several recent analyst reports. Oppenheimer began coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, January 7th. They issued an “outperform” rating and a $500.00 price objective on the stock. Canaccord Genuity Group boosted their target price on Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. Needham & Company LLC lowered their price target on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a research report on Thursday, February 12th. Truist Financial cut their price objective on Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating on the stock in a report on Thursday, January 8th. Finally, Bank of America reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $477.96.

Alnylam Pharmaceuticals Stock Up 1.2%

Shares of NASDAQ ALNY opened at $331.24 on Friday. The stock has a market cap of $43.93 billion, a P/E ratio of 193.71 and a beta of 0.35. The business’s fifty day simple moving average is $361.89 and its 200-day simple moving average is $419.66. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $495.55. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 12th. The biopharmaceutical company reported $0.82 EPS for the quarter, missing the consensus estimate of $1.43 by ($0.61). The company had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.16 billion. Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The company’s revenue for the quarter was up 84.9% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.65) earnings per share. As a group, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 9,577 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $362.86, for a total transaction of $3,475,110.22. Following the completion of the transaction, the chief executive officer owned 78,411 shares in the company, valued at $28,452,215.46. The trade was a 10.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Tolga Tanguler sold 1,959 shares of the stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $310.08, for a total transaction of $607,446.72. Following the completion of the sale, the executive vice president directly owned 31,769 shares in the company, valued at approximately $9,850,931.52. This represents a 5.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 36,578 shares of company stock valued at $12,416,105. 1.50% of the stock is currently owned by company insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.